Skip to main content

Table 1 Demographic and clinical characteristics at baseline

From: Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study

Characteristics

Non-TMP-SMZ group

n = 112

TMP-SMZ group

n = 195

Total

n = 307

P values

Sex, no. (%)

0.876c

 Male

61 (54.5)

108 (55.4)

169 (55.0)

 

 Female

51 (45.5)

87 (44.6)

138 (45.0)

 

Age (y)

0.820d

 Mean (range)

5.1 (0.1–14.0)

5.0 (0.1–14.0)

5.1 (0.1–14.0)

 

 Median (IQR)

5.0 (1.5–7.8)

5.0 (2.0–8.0)

5.0 (1.8–8.0)

 

Weight (kg)

0.749d

 Mean (range)

18.4 (3.6–45.0)

18.4 (3.5–50.0)

18.4 (3.5–50.0)

 

 Median (IQR)

18.0 (11.1–24.0)

18.0 (11.6–24.0)

18.0 (11.5–24.0)

 

Topography

1.000e

 Head and neck

23 (20.5)

41 (21.0)

64 (20.8)

 

 Limbs

61 (54.5)

106 (54.4)

167 (54.4)

 

  Upper

22 (19.6)

37 (19.0)

59 (19.2)

 

  Lower

39 (34.8)

69 (35.4)

108 (35.2)

 

 Trunk

28 (25.0)

48 (24.6)

76 (24.8)

 

Diagnosis, no. (%)

0.982e

 Vascular tumors

47 (42.0)

92 (47.2)

139 (45.3)

 

  Kaposiform hemangioendothelioma

40 (35.7)

81 (41.5)

121 (39.4)

 

  Tufted angioma

7 (6.3)

11 (5.6)

18 (5.9)

 

 Vascular malformations

65 (58.0)

103 (52.8)

168 (54.7)

 

  Venous malformation

22 (19.6)

35 (17.9)

57 (18.6)

 

  Arteriovenous malformation

1 (0.9)

5 (2.6)

6 (2.0)

 

  Lymphatic malformation

18 (16.1)

31 (15.9)

49 (16.0)

 

  Combined vascular malformation

16 (14.3)

22 (11.3)

38 (12.4)

 

  Vascular malformation associated with other anomalies

8 (7.1)

10 (5.1)

18 (5.9)

 

Previous therapies, no. (%)a

81 (72.3)

152 (77.9)

233 (75.9)

0.217e

 Partial resection

32 (28.6)

46 (23.6)

78 (25.4)

 

 Sclerotherapy

23 (20.5)

39 (20.0)

62 (20.2)

 

 Embolization

16 (14.3)

22 (11.3)

38 (12.4)

 

 Laser

8 (7.1)

15 (7.7)

23 (7.5)

 

 Medical therapies

41 (36.6)

60 (30.8)

101 (32.9)

 

  Propranolol

16 (14.3)

21 (18.8)

37 (12.1)

 

  Corticosteroids

26 (23.2)

37 (33.0)

63 (20.5)

 

  Vincristine

5 (4.5)

8 (4.1)

13 (4.2)

 

 Supportive care treatmentsb

29 (25.9)

40 (20.5)

69 (22.5)

 

Disease activity

0.526d

 Mean (range)

2.9 (1.0–4.0)

2.8 (1.0–4.0)

2.8 (1.0–4.0)

 

 Median (IQR)

3.0 (2.0–3.0)

3.0 (2.0–3.0)

3.0 (2.0–3.0)

 
  1. TMP-SMZ Trimethoprim-sulfamethoxazole, y year, IQR Interquartile range
  2. aOne patient may have received more than one treatment regimen
  3. bSupportive care treatments included anti-coagulation, fresh frozen plasma, cryoprecipitate and packed red blood cells
  4. cP value was calculated with chi-square test
  5. dP value was calculated using the Mann–Whitney U test
  6. eP value was calculated using the Pearson chi-square test